The human body harbors around 100 trillion microbial organisms throughout body known as the microbiota, and the genomes of all the microflora is known as microbiome. These microorganisms play a significant role in human health, including metabolism and immunity. Any alteration in composition of microbiome can lead to disease such as ulcerative colitis, irritable bowel syndrome, Crohn’s disease, psoriasis, asthma and cardiovascular diseases. Major focus is on studying the gut microbes in diagnostics, as there is observed alteration in types of microbes at times of inflammatory bowel diseases such as Crohn’s disease or ulcerative colitis.
Hemophilia is a genetic bleeding disorder caused due to deficiency or missing protein needed for clotting, due to which the normal blood clotting does not occur. The episodes of bleeding depends on the severity of hemophilia. There are two main forms of hemophilia namely Hemophilia A and Hemophilia B. Hemophilia A is approximately four times more prevalent than hemophilia B. Incidence of hemophilia A is one in five thousand live male births.
The government health departments worldwide are actively seeking to achieve the welfare of the people and society by primarily focusing on the extending life expectancy, quality of life, free distribution of medications and so on. Rising prevalence of chronic diseases, and the corresponding increasing drug discovery and development studies performed by major pharmaceutical manufacturers and research organizations are driving the preventive healthcare technologies, products and services market.
Periodontal therapeutics are the non-surgical treatment for the periodontal diseases. Periodontal diseases are the infections of the structures around the teeth including the gums, the cementum that covers the root, the periodontal ligament and the aveolar bone.
Enteric diseases are caused by microscopic pathogens that enter the body through the mouth or intestinal route, fundamentally because of eating or drinking any contaminated foods or fluids. The immune system of the body and the strength of the pathogen cumulatively decide the fate of the infection whether it will be acute or chronic.
Immunization through vaccines are done to raise the immune responses leading to the generation of antibodies or cell-mediated responses that would combat infectious agents or any noninfectious conditions. The most critical factor for the successful immunization is to choose the route of administration by which a vaccine is brought into contact with the body.
Western blotting, or protein immunoblot, is the technique used for detection and quantification of specific proteins in a sample. This technique forms a major contributor in molecular diagnostics market. Growing prevalence of HIV worldwide, increasing range of applications of western blotting and extensive R&D initiatives being undertaken in this space by biotechnology and pharmaceutical companies are the major drivers of the global western blotting market.
The report titled “Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market - Growth, Future Prospects, and Competitive Analysis, 2025 – 2033” offers strategic insights into the overall ABSSSI treatment market along with the market size and estimates for the duration 2020 to 2033. The said research study cover in-depth analysis of multiple market segments based on type of infection, pathogen, drug, and different geographies.
RFID inlays are smart labels comprising chip and antenna which are bonded on a polyethylene terephthalate (PET) layer. In the overall RFID system, the RFID inlays act as the component which stores information regarding the product or component to which they are attached.
Depth filtration is generally a porous filtration medium to filter high load of particles, where particle retain throughout the filtration medium. Increase in demand of depth filters in various industries due to its efficiency and applicability, availability of technologically advance depth filter, increase in number of industries are primarily driving the growth of depth filtration market globally.
The drugs by therapeutic area market covers pharmaceutical products classified according to the diseases and medical conditions they are designed to treat. Major therapeutic areas include oncology, cardiovascular diseases, diabetes and other metabolic disorders, neurological conditions, infectious diseases, respiratory disorders, immunology, gastrointestinal diseases, dermatology, ophthalmology, women’s health and rare diseases. The category includes prescription drugs, generic medicines, biologics, biosimilars, vaccines and advanced therapies.
The wider global pharmaceutical market provides an appropriate benchmark for evaluating growth across therapeutic drug categories. One current industry estimate projects the pharmaceutical market to increase from approximately USD 1.88 trillion in 2026 to USD 3.22 trillion by 2035, representing a compound annual growth rate of 6.15%. North America held the largest regional share in 2025, while Asia-Pacific is expected to demonstrate notable growth through 2035.
Market growth is being supported by the increasing prevalence of chronic and age-related diseases. Rising cases of cancer, diabetes, cardiovascular disorders, arthritis, respiratory diseases and neurological conditions are creating sustained demand for effective treatments. Population ageing, lifestyle changes, urbanization and improved access to diagnosis are further expanding the number of patients receiving long-term therapy.
Oncology remains an important area for pharmaceutical research and commercial investment. Development activity includes targeted therapies, immune checkpoint inhibitors, antibody-drug conjugates, cell therapies and personalized cancer treatments. Diabetes and obesity drugs are also recording strong demand, supported by the wider use of GLP-1 and other metabolic treatments. Neurology research is expanding across Alzheimer’s disease, Parkinson’s disease, epilepsy and mental health conditions.
Biologic drugs and biosimilars represent major market trends. Biologics are increasingly used to treat cancer, autoimmune diseases and rare disorders, while biosimilars can improve access after reference-product patent expiry. Pharmaceutical companies are also developing gene therapies, RNA-based medicines and other advanced treatments for conditions with limited existing options.
Precision medicine is influencing drug development across multiple therapeutic areas. Biomarkers, genomic testing and companion diagnostics help identify patients who are more likely to respond to specific medicines. Artificial intelligence is also being used for target identification, clinical-trial planning and analysis of real-world treatment data.
Market expansion may be restrained by high research costs, lengthy clinical development, regulatory uncertainty and drug-pricing pressure. Patent expirations can reduce revenue for branded products, while safety concerns or unsuccessful clinical trials may delay commercial launches. Access and reimbursement remain major challenges for expensive biologics and advanced therapies.
Acute Market Reports provides therapeutic-area drug research covering product classes, disease indications, routes of administration, distribution channels, company pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, investors, healthcare providers and distributors evaluate treatment demand and growth prospects through 2035.